Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Alex Azar - Sworn In At The White House
Politics

Drug makers question idea to shake up how Medicare pays for certain drugs

By Erin Mershon and Ike Swetlitz

Biotech

Biogen’s rain-making rare-disease drug hits a sales slump

By Damian Garde

Food addiction
In the Lab

They were commercial flops. But can weight loss drugs be used to treat addiction?

By Meghana Keshavan

Biotech

Prothena scraps lead drug following mid-stage study failure

By Adam Feuerstein

Adam's Take

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

By Adam Feuerstein

Interacting chromatin chains
Biotech

Startup unwinds the role of chromatin to target epigenetic changes in cancer

By Elizabeth Cooney

Novartis International pharmaceutical
Biotech

For the first CAR-T therapy, early sales are weak but hopes are still sky high

By Damian Garde

Dr. John Maraganore
Biotech

Trade secrets battle between Alnylam, Dicerna is just one of many

By Jonathan Saltzman — Boston Globe

Merck logo
Biotech

Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data

By Damian Garde

FDA campus
Biotech

Alkermes’s depression drug is back on track after an FDA ‘misunderstanding’

By Damian Garde

Akili screenshot
Business

A digital medicine company tries to adopt pharma’s patent game. Will it work?

By Rebecca Robbins

Biotech

Pfizer latest to test gene therapy for Duchenne muscular dystrophy

By Elizabeth Cooney

Elizabeth Holmes
Business

‘Therabros’ and ‘disappeared’ staffers: the 8 juiciest things we learned from John Carreyrou’s new Theranos book

By Rebecca Robbins

Alexion Pharmaceuticals Inc
Business

Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

By Adam Feuerstein

Adam's Take

Biogen and the badly needed gene therapy acquisition that got away

By Adam Feuerstein

David Hung
Biotech

The stint that never happened? Biotech vet David Hung wipes Axovant from his work history

By Damian Garde

Future naloxone
Biotech

The next naloxone? Companies, academics search for better overdose-reversal drugs

By Max Blau

Cancer in China
Biotech

Chinese patients get these cancers at an alarming rate. Now drug makers see an opportunity

By Rebecca Robbins

Pharma

Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities

By Adam Feuerstein

STAT Plus panel
Biotech

Why are some of New York’s top investors bullish on biotech? The science is getting better

By Adam Feuerstein

Biotech

Should Bristol-Myers panic over Incyte’s skin cancer failure?

By Damian Garde

AP
Biotech

Incyte’s cancer drug fails trial, marking major blow for immunotherapy combination treatment

By Adam Feuerstein

The Readout LOUD

LISTEN: The FDA’s cold shoulder, the latest CAR-T contender, and how Grindr relates to personal genetics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Medicine
Pharma

Drug makers have to post policies for patients seeking experimental medicines. Not all do

By Erin Mershon

Richard Vinci
Biotech

Trials for potential ALS treatment using stem cells spark cautious hope

By Jonathan Saltzman — Boston Globe

CAR-T
Biotech

They built a game-changing cancer-killing therapy. Now they’re taking on a new kind of CAR-T therapy

By Rebecca Robbins

Adam's Take

Experimental drug might reduce fat in blood, but a NASH cure? Not so fast

By Adam Feuerstein

Business

Alkermes stumbles as FDA refuses to review depression drug

By Adam Feuerstein

Stock Market
Biotech

The biotech scorecard for the 2nd quarter: 12 make-or-break industry events to watch

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.